血管紧张素-(1-7)通过EPAC/Rap1依赖性抑制O-GlcNAc转移酶减轻视网膜蛋白O-GlcNAcylation
该研究在高脂饮食小鼠和MIO-M1视网膜Müller细胞中探讨肾素-血管紧张素系统对 retinal 蛋白O-GlcNAcylation的影响。结果显示卡托普利经Mas受体激活减轻视网膜蛋白O-GlcNAcylation,血管紧张素-(1-7)通过EPAC/Rap1/OGT信号轴抑制O-GlcNAc转移酶活性,并防止高糖或O-GlcNAcase抑制剂诱导的线粒体超氧化物升高。
要点
- 卡托普利减轻高脂饮食小鼠视网膜蛋白O-GlcNAcylation,该效应依赖Mas受体激活。
- 血管紧张素-(1-7)通过EPAC/Rap1而非PKA信号通路抑制OGT活性,减少蛋白O-GlcNAcylation。
- 血管紧张素-(1-7)信号可阻止O-GlcNAcase抑制剂或高糖条件下MIO-M1细胞线粒体超氧化物升高。
核心结论
- 血管紧张素-(1-7)通过EPAC/Rap1/OGT信号轴抑制视网膜蛋白O-GlcNAcylation。
研究设计与样本
- 研究纳入高脂饮食小鼠,长期给予卡托普利或卡托普利联合Mas受体拮抗剂A779,分析视网膜匀浆。
- 研究对暴露于补充血管紧张素-(1-7)培养基的人MIO-M1视网膜Müller细胞裂解物进行类似分析。
- 研究通过操控培养条件影响己糖胺生物合成通路和/或Mas受体下游信号。
主要发现
- 高脂饮食小鼠视网膜中,卡托普利以依赖Mas受体激活的方式减轻蛋白O-GlcNAcylation。
- MIO-M1细胞中,血管紧张素-(1-7)或腺苷酸环化酶激活足以提高cAMP水平并抑制O-GlcNAcylation。
- cAMP对O-GlcNAcylation的抑制作用依赖EPAC而非PKA,并可由小GTP酶Rap1的组成性激活变体重现。
- 研究提供证据表明cAMP和血管紧张素-(1-7)通过抑制OGT活性来抑制O-GlcNAcylation。
- 暴露于O-GlcNAcase抑制剂或高糖培养条件的细胞线粒体超氧化物水平升高,血管紧张素-(1-7)信号可阻止该效应。
临床怎么用
- 该研究提示肾素-血管紧张素系统干预可能通过Mas受体/EPAC/Rap1/OGT轴调节视网膜蛋白O-GlcNAcylation,为糖尿病视网膜病变机制研究提供线索。
- 血管紧张素-(1-7)信号在细胞模型中可防止高糖或O-GlcNAcase抑制剂诱导的线粒体超氧化物升高,提示其潜在抗氧化作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: O-GlcNAcylation of cellular proteins contributes to the pathophysiology of diabetes and evidence supports a role for augmented O-GlcNAcylation in diabetic retinopathy. The aim of this study was to investigate the impact of the renin-angiotensin system on retinal protein O-GlcNAcylation. METHODS: Mice fed a high-fat diet were treated chronically with the angiotensin-converting enzyme inhibitor captopril or captopril plus the angiotensin-(1-7) Mas receptor antagonist A779. Western blotting and quantitative polymerase chain reaction were used to analyze retinal homogenates. Similar analyses were performed on lysates from human MIO-M1 retinal Müller cell cultures exposed to media supplemented with angiotensin-(1-7). Culture conditions were manipulated to influence the hexosamine biosynthetic pathway and/or signaling downstream of the Mas receptor. RESULTS: In the retina of mice fed a high-fat diet, captopril attenuated protein O-GlcNAcylation in a manner dependent on Mas receptor activation. In MIO-M1 cells, angiotensin-(1-7) or adenylate cyclase activation were sufficient to enhance cyclic AMP (cAMP) levels and inhibit O-GlcNAcylation. The repressive effect of cAMP on O-GlcNAcylation was dependent on exchange protein activated by cAMP (EPAC), but not protein kinase A, and was recapitulated by a constitutively active variant of the small GTPase Rap1. We provide evidence that cAMP and angiotensin-(1-7) act to suppress O-GlcNAcylation by inhibition of O-GlcNAc transferase (OGT) activity. In cells exposed to an O-GlcNAcase inhibitor or hyperglycemic culture conditions, mitochondrial superoxide levels were elevated; however, angiotensin-(1-7) signaling prevented the effect. CONCLUSIONS: Angiotensin-(1-7) inhibits retinal protein O-GlcNAcylation via an EPAC/Rap1/OGT signaling axis.
引用
- Dierschke SK, Toro AL, Barber AJ, et al. Angiotensin-(1-7) Attenuates Protein O-GlcNAcylation in the Retina by EPAC/Rap1-Dependent Inhibition of O-GlcNAc Transferase. Invest Ophthalmol Vis Sci. 2020. PMID: 32068794. doi:10.1167/iovs.61.2.24
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。